{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:16:05Z","timestamp":1788250565930,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.metabol.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T03:32:18Z","timestamp":1494387138000},"page":"22-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins"],"prefix":"10.1016","volume":"73","author":[{"given":"Mina","family":"Amiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Ramezani Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Nahidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereidoun","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Carmina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2017.05.001_bb0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijgo.2008.05.017","article-title":"Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome","volume":"103","author":"\u00d6zdemir","year":"2008","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.metabol.2017.05.001_bb0010","first-page":"358","article-title":"Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome","volume":"36","author":"Carmina","year":"2013","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.metabol.2017.05.001_bb0015","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.metabol.2015.06.011","article-title":"Increased thrombin generation in women with polycystic ovary syndrome: a pilot study on the effect of metformin and oral contraceptives","volume":"64","author":"Glintborg","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.05.001_bb0020","first-page":"16057","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat Rev"},{"key":"10.1016\/j.metabol.2017.05.001_bb0025","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.05.001_bb0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/00365513.2014.936676","article-title":"Polycystic ovary syndrome: metabolic consequences and long-term management","volume":"74","author":"Carmina","year":"2014","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.metabol.2017.05.001_bb0035","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1210\/jc.2014-3196","article-title":"Approach to the patient: contraception in women with polycystic ovary syndrome","volume":"100","author":"Yildiz","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.05.001_bb0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.contraception.2004.12.005","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 20 \u03bcg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism","volume":"71","author":"Klipping","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.metabol.2017.05.001_bb0045","first-page":"3161","article-title":"Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: arandomized study 1","volume":"85","author":"Morin-Papunen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.05.001_bb0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humrep\/dem379","article-title":"Cyproterone acetate\/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy","volume":"23","author":"Franks","year":"2008","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.05.001_bb0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/humrep\/del407","article-title":"Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis","volume":"22","author":"Nader","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.05.001_bb0060","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3109\/09513590.2014.943725","article-title":"Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies","volume":"30","author":"Mendoza","year":"2014","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0065","first-page":"175","article-title":"Oral contraceptives in polycystic ovary syndrome","volume":"39","author":"Helvaci","year":"2014","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2017.05.001_bb0075","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.metabol.2017.05.001_bb0080","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2010.03.004","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Moher","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0085","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.fertnstert.2008.09.034","article-title":"Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy","volume":"93","author":"Teede","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.05.001_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0095","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.metabol.2017.05.001_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2017.05.001_bb0105","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2017.05.001_bb0110","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.metabol.2017.05.001_bb0115","series-title":"Trim and fill: a simple funnel plot based method of testing and adjusting for publication bias in meta-analyses","author":"Taylor","year":"1998"},{"key":"10.1016\/j.metabol.2017.05.001_bb0120","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1093\/humrep\/deh485","article-title":"Impact of overweight and underweight on assisted reproduction treatment","volume":"19","author":"Fedorcs\u00e1k","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.05.001_bb0125","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0026-0495(98)90257-8","article-title":"Effects of oral contraceptives on free fatty acid metabolism in women","volume":"47","author":"Jensen","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.05.001_bb0130","first-page":"deq301","article-title":"The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies","author":"Halperin","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.05.001_bb0135","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cen.13112","article-title":"Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial","volume":"85","author":"Orio","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0140","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.1.01840","article-title":"Effects of metformin and ethinyl estradiol\u2013cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome","volume":"152","author":"Rautio","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/qjmed\/94.1.31","article-title":"Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol\/cyproterone acetate","volume":"94","author":"Armstrong","year":"2001","journal-title":"QJM"},{"key":"10.1016\/j.metabol.2017.05.001_bb0150","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/humrep\/17.7.1729","article-title":"Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol\u2013cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study","volume":"17","author":"Elter","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.05.001_bb0155","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0015-0282(02)02993-X","article-title":"Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives","volume":"77","author":"Mastorakos","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.05.001_bb0160","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1210\/jc.2003-030328","article-title":"Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel","volume":"88","author":"Cagnacci","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.05.001_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1783\/1471189041261636","article-title":"An observational study of Yasmin in the management of women with polycystic ovary syndrome","volume":"30","author":"Palep-Singh","year":"2004","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.metabol.2017.05.001_bb0170","first-page":"194","article-title":"Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome","volume":"25","author":"Liqun","year":"2005","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.metabol.2017.05.001_bb0175","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.fertnstert.2005.07.1306","article-title":"Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome","volume":"85","author":"Mastorakos","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.05.001_bb0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13625180600983082","article-title":"Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome","volume":"12","author":"Pehlivanov","year":"2007","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.metabol.2017.05.001_bb0185","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/09513590802217027","article-title":"Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome","volume":"24","author":"Wu","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00404-007-0401-x","article-title":"The effect of ethinyl estradiol\u2013cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome","volume":"277","author":"Gul","year":"2008","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.metabol.2017.05.001_bb0195","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2169\/internalmedicine.48.2177","article-title":"The effect of ethinylestradiol (EE)\/cyproterone acetate (CA) and EE\/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS)","volume":"48","author":"Bilgir","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.metabol.2017.05.001_bb0200","first-page":"423","article-title":"Effects of an EE\/CA compared with EE\/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome","volume":"4","author":"Kebapcilar","year":"2009","journal-title":"Cent Eur J Med"},{"key":"10.1016\/j.metabol.2017.05.001_bb0205","series-title":"Evaluation of the clinical and biochemical effects of medical therapy in women with polycystic ovary syndrome","author":"Mahmood","year":"2009"},{"key":"10.1016\/j.metabol.2017.05.001_bb0210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.fertnstert.2008.07.008","article-title":"The effects of oral contraceptives including low-dose estrogen and drospirenone on the concentration of leptin and ghrelin in polycystic ovary syndrome","volume":"92","author":"Sagsoz","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.05.001_bb0215","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/humrep\/dep459","article-title":"Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome","volume":"25","author":"Chen","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.metabol.2017.05.001_bb0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.contraception.2010.02.009","article-title":"Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome","volume":"82","author":"Kriplani","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.metabol.2017.05.001_bb0225","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/09513590.2010.507283","article-title":"The impact of oral contraceptives and metformin on anti-Mullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia","volume":"27","author":"Panidis","year":"2011","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0230","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/09513590.2010.521265","article-title":"Effect of ethinylestradiol\/cyproterone acetate on endothelial function in young non-obese women with polycystic ovary syndrome: a pilot study","volume":"27","author":"Naka","year":"2011","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0235","doi-asserted-by":"crossref","DOI":"10.3109\/09513590.2011.613971","article-title":"Effects of ethinyl estradiol\u2013cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome","author":"Karabulut","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.metabol.2017.05.001_bb0240","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.fertnstert.2012.06.035","article-title":"Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome","volume":"98","author":"Bhattacharya","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2017.05.001_bb0245","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.contraception.2012.07.005","article-title":"Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination","volume":"87","author":"Aydin","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.metabol.2017.05.001_bb0250","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00404-014-3217-5","article-title":"Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial","volume":"290","author":"Kahraman","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.metabol.2017.05.001_bb0255","doi-asserted-by":"crossref","first-page":"109","DOI":"10.14310\/horm.2002.1526","article-title":"The influence of combined oral contraceptives containing drospirenone on hypothalamic\u2013pituitary\u2013adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome","volume":"14","author":"Macut","year":"2015","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.metabol.2017.05.001_bb0260","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3109\/09513590.2015.1006187","article-title":"Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up","volume":"31","author":"Yildizhan","year":"2015","journal-title":"Gynecol Endocrinol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:13:11Z","timestamp":1758427991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517301427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":52,"alternative-id":["S0026049517301427"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.05.001","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}